RT Book, Section A1 Michaelis, Laura C. A2 Dieter, Robert S. A2 Dieter, Raymond A. A2 Dieter, Raymond A. SR Print(0) ID 1126489466 T1 Hypercoagulable States Associated with Malignancy T2 Venous and Lymphatic Diseases YR 2011 FD 2011 PB McGraw-Hill Medical PP New York, NY SN 9780071601580 LK accesscardiology.mhmedical.com/content.aspx?aid=1126489466 RD 2024/03/28 AB Malignancy, whether in the form of a solid tumor or hematologic neoplasm, constitutes a significant risk for hypercoagulability. Venous and arterial thromboembolic diseases are important causes of death and morbidity in individuals with cancer.1,2,3,4 It is estimated that venous clots complicate the clinical course of about 20% of all patients diagnosed with or treated for a malignancy,5,6 and even that figure may underestimate the problem, given autopsy findings of thrombosis in as many as 50% of patients with cancer.7